Search - tctmd.com

Displaying 161 - 180 of 204

Sort: Relevancy | Date

News Conference News EuroPCR 2018

New ORBITA Insights: Invasive Physiology Tests Track Closely With Ischemia, but Not Symptom Improvement

Shelley Wood

May 22, 2018

News Daily News

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

Michael O'Riordan

May 01, 2018

News Features

ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging

Michael O'Riordan

March 23, 2018

News Conference News ACC 2018

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

Michael O'Riordan

March 10, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Conference News ACC 2018

Flu Vaccine Reduces Mortality, Hospitalization in HF Patients: Meta-analysis

Michael O'Riordan

March 01, 2018

News Conference News ISC 2018

COMPASS Analysis Explores Impact of Low-Dose Rivaroxaban Plus Aspirin on Stroke

Todd Neale

January 25, 2018

News Daily News

High Rate of Clinical Events at 6 Months for Ischemic CVD Patients

Michael O'Riordan

January 19, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2017

Shelley Wood

November 29, 2017

News Features

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Michael O'Riordan

November 27, 2017

News Conference News AHA 2017

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Michael O'Riordan

November 15, 2017

News Daily News

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Michael O'Riordan

October 26, 2017

News Daily News

Ischemic Heart Disease the Leading Cause of Death Globally

Michael O'Riordan

September 19, 2017

News Features

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

Todd Neale

September 15, 2017

News Conference News ESC 2017

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

Michael O'Riordan

August 30, 2017

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

Todd Neale

August 27, 2017

News Daily News

ADAPT-DES at 2 Years Offers Insights Into Provider Strategies and Aspirin Monotherapy Beyond 1 Year

Yael L. Maxwell

August 07, 2017

News Daily News

Many Stroke Patients Stop Statins or Never Start, With Dire Consequences

Michael O'Riordan

August 02, 2017

News Daily News

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

Leah Lawrence

July 24, 2017

News Daily News

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

L.A. McKeown

May 23, 2017

Advertisement

New ORBITA Insights: Invasive Physiology Tests Track Closely With Ischemia, but Not Symptom Improvement

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Flu Vaccine Reduces Mortality, Hospitalization in HF Patients: Meta-analysis

COMPASS Analysis Explores Impact of Low-Dose Rivaroxaban Plus Aspirin on Stroke

High Rate of Clinical Events at 6 Months for Ischemic CVD Patients

TCTMD’s Top 10 Most Popular Stories for November 2017

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Ischemic Heart Disease the Leading Cause of Death Globally

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

ADAPT-DES at 2 Years Offers Insights Into Provider Strategies and Aspirin Monotherapy Beyond 1 Year

Many Stroke Patients Stop Statins or Never Start, With Dire Consequences

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content